Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm

Cancer Family

Intestinal Neoplasm

CI-CAN-00000209Explore in graph →

Non-malignant1,892 active trials21 approved drugs383 evidence items

NCIt: C3141
MeSH: D007414

Overview
Statistics
Survival
Genomics28
Variants & evidence383
Drugs80
Trials9155
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (371)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 276–300 of 371 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
· Scand J Gastroenterol · 2014 · PMID 24256029 · validated civic_curation pubmed
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
· Ann Oncol · 2013 · PMID 24146218 · validated civic_curation pubmed
Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.
· J Cancer Res Clin Oncol · 2016 · PMID 27177629 · validated civic_curation pubmed
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
· Cancer Chemother Pharmacol · 2015 · PMID 25322874 · validated civic_curation pubmed
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
· J Clin Oncol · 2004 · PMID 14993230 · validated civic_curation pubmed
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
· Ann Oncol · 2019 · PMID 31038663 · validated civic_curation pubmed
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Showing 276–300 of 371 publications

← Previous
1
…
11
12
13
14
15
Next →

· Nature · 2012 · PMID 22722830 · validated civic_curation pubmed

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

· Nat Med · 2012 · PMID 22270724 · validated civic_curation pubmed

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

· Clin Cancer Res · 2016 · PMID 26888827 · validated civic_curation pubmed

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

· Cancer Discov · 2016 · PMID 27325282 · validated civic_curation pubmed

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

· Cancer Discov · 2016 · PMID 26546295 · validated civic_curation pubmed

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

· Clin Cancer Res · 2017 · PMID 28424201 · validated civic_curation pubmed

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

· J Natl Cancer Inst · 2016 · PMID 26563355 · validated civic_curation pubmed

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy.

· Cureus · 2022 · PMID 35815302 · validated civic_curation pubmed

Major response to imatinib mesylate in KIT-mutated melanoma.

· J Clin Oncol · 2008 · PMID 18421059 · validated civic_curation pubmed

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.

· Int J Colorectal Dis · 2016 · PMID 26561417 · validated civic_curation pubmed

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

· N Engl J Med · 2016 · PMID 27959684 · validated civic_curation pubmed

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

· Cancer Discov · 2013 · PMID 23729478 · validated civic_curation pubmed

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

· Br J Cancer · 2009 · PMID 19603018 · validated civic_curation pubmed

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.

· Cancer Discov · 2015 · PMID 25673644 · validated civic_curation pubmed

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.

· Oncotarget · 2016 · PMID 26989027 · validated civic_curation pubmed

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.

· Cold Spring Harb Mol Case Stud · 2016 · PMID 27626067 · validated civic_curation pubmed

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

· Clin Cancer Res · 2016 · PMID 26933125 · validated civic_curation pubmed

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

· Ann Oncol · 2018 · PMID 29538669 · validated civic_curation pubmed

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

· Br J Cancer · 2015 · PMID 26633560 · validated civic_curation pubmed